JMP Securities raised the firm’s price target on Crinetics to $80 from $60 and keeps an Outperform rating on the shares. The PATHFNDR-2 profile should allow paltusotine to become the market-leading acromegaly drug, the analyst tells investors in a research note. The firm thinks approval in 2025 with a broad label is likely.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRNX:
- 3 Best Stocks to Buy Now, 3/20/2024, According to Top Analysts
- Crinetics Pharmaceuticals’ Paltusotine Shows Promising Results
- Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
- Crinetics’ paltusotine in acromegaly meets all Phase 3 study endpoints
- Crinetics price target raised to $54 from $48 at Oppenheimer
